FDA Set to Rule on Three Drug Applications

Regulators are expected to announce decisions this week on applications from Capricor, Savara and Beren Therapeutics.

Updated on Nov. 16, 2026 in Biotech

Bold flat-color editorial illustration of unlabeled amber vials and white cold-storage canisters in a clean laboratory setting, evoking regulatory review of experimental therapies.
The FDA is set to rule this week on three drug applications from Capricor, Savara and Beren Therapeutics, after rejecting Summit Therapeutics' lung cancer drug for insufficient evidence. AI Illustration. Upload story photo >

The FDA is set to announce its verdict on three applications this week, following a Complete Response Letter it issued to Summit Therapeutics on Sunday, November 16, 2026. The agency cited insufficient evidence of effectiveness because the lung cancer drug did not show a statistically significant improvement in overall survival.

Why it matters

The decisions will determine whether experimental therapies for muscular dystrophy, a rare lung disease and a neurological condition reach patients in the United States. Each application rests on trial data that regulators have weighed differently, making the outcomes a test of how the agency evaluates evidence in rare-disease treatments.

The evidence comes from Phase 3 trial results and a July advisory committee vote of 9-3 against Deramiocel's evidence for DMD-related cardiomyopathy. Adrabetadex reduced annual neurological disease progression by 43%, but the FDA's final decisions on all three applications remain unannounced.

The players

Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell-based therapies for cardiac and muscular conditions, including Deramiocel.

Savara

Savara is a biopharmaceutical company developing Molbreevi for autoimmune pulmonary alveolar proteinosis, a rare lung disease.

Beren Therapeutics

Beren Therapeutics is a biotechnology company developing Adrabetadex for neurological disease progression.

Summit Therapeutics

Summit Therapeutics is a biopharmaceutical company that received a Complete Response Letter for its lung cancer biologics application.

The details

Capricor is seeking approval for Deramiocel, an experimental cell therapy meant to slow loss of arm function in patients older than nine with Duchenne muscular dystrophy, after the FDA rejected its first application in July 2025. Savara's Molbreevi, targeting autoimmune pulmonary alveolar proteinosis, received priority review, and its Phase 3 Impala-2 trial met its primary endpoint.

Timeline

  1. July 2025: FDA rejected Capricor's first Deramiocel application.

  2. July 2026: An advisory committee voted 9-3 against Deramiocel evidence.

  3. November 16, 2026: FDA issued a Complete Response Letter to Summit Therapeutics.

  4. November 17, 2026: Beren Therapeutics expects a regulatory decision on Adrabetadex.

  5. November 22, 2026: Molbreevi decision date after extension.

Regulatory Context

The applications are being reviewed under the FDA's priority review pathway for rare-disease therapies, which has produced mixed outcomes, as Capricor's July 2025 rejection shows. The pending decisions will show whether the agency's standards for statistically significant survival or functional benefit remain consistent across rare-disease applications.

If approved, Deramiocel could offer patients with Duchenne muscular dystrophy a way to slow arm function loss, while Molbreevi would give a treatment option to people with a rare lung disease. The decisions will determine whether these therapies become available to patients in the United States.

The takeaway

Regulatory decisions on rare-disease therapies often hinge on how trial endpoints are weighed, so readers should watch for the FDA's stated reasons when decisions are announced. Outcomes for all three applications will clarify how the agency applies its evidence standards.

What happens next

The FDA is expected to announce its decision on Molbreevi by November 22, 2026, and Beren Therapeutics expects a regulatory decision on Adrabetadex on November 17, 2026.

Further reading

Follow the latest developments in Biotech coverage for more on drug approvals and regulatory decisions.